AI in drug discovery adoption by type of organization worldwide 2023

According to a survey from 2023, 75 percent of so-called 'AI-first' biotech companies stated they use artificial intelligence in drug discovery substantially. This is expected since these are companies for which the usage of AI/machine learning is at the very core of their research. All in all, the AI adoption level is five times lower in 'classic' pharma and biotech companies.

Adoption level of AI in drug discovery worldwide as of 2023, by organization type

Characteristic	None	Limited	Occasional	Substantial	Extensive
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-
-	-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

2023

More information

Region

Worldwide

Survey time period

as of June 2023

Number of respondents

102 individuals across academia, industry, and funders

Supplementary notes

Original question: “How would you characterize your organization’s usage of AI tools to support the use case family?” (Respondents may overlap across use cases and can only choose one option per use case, average use case option per respondent was used to determine usage by sector)
Percentage points missing/exceeding 100 percent are probably due to rounding.

* Including both AI-first biotech and pharma/biotech companies.

Citation formats